Cost Analysis for Pathologic Evaluation of Metastatic Carcinoma of Unknown Origin

摘要

Metastatic carcinomas of unknown origin comprise 10% to 15% of new referrals to oncology clinics. Although the cost of attempting, to determine the site of origin by using immunohistochemical tests may be as. high-as